Guillain-Barré Syndrome Following the BNT162b2 mRNA COVID-19 Vaccine
Description
CONCLUSION: Guillain-Barré syndrome after COVID-19 vaccination is responsive to treatment. The benefits of administering the vaccine outweigh the risks. Due to the negative impact of COVID-19, it is essential to recognize the development of
